What Is the Mavacamten Mechanism of Action?

Mavacamten works by directly dialing down the molecular motor inside heart muscle cells. It selectively and reversibly inhibits cardiac myosin, the protein engine that drives each heartbeat’s contraction, and it does so at the most fundamental level of the muscle’s machinery: the sarcomere. That makes it genuinely different from older heart medications, which act on electrical signals or hormone receptors rather than on the contractile apparatus itself. Understanding how mavacamten operates at the molecular scale explains why it has changed the treatment landscape for hypertrophic cardiomyopathy, and why it comes with specific risks that require careful monitoring.

The Problem Mavacamten Was Designed to Solve

Hypertrophic cardiomyopathy, or HCM, is the most common inherited heart disease. The heart muscle thickens abnormally, and in many patients, the thickened tissue obstructs blood flow out of the left ventricle during each contraction. Older treatments like beta-blockers slow the heart rate and reduce the force of contraction indirectly, through the nervous system, but they don’t address the root cause: too many myosin motors firing at once inside the muscle fiber.

At the sarcomere level, HCM mutations tend to make the contractile machinery hyperactive. Research has shown that mutations in genes like MYBPC3, which encodes a protein that normally acts as a brake on myosin, lead to a reciprocal increase in myosin contractility when that braking protein is depleted.¹ The result is a heart that squeezes too hard, relaxes too slowly, and consumes more energy than it should. Beta-blockers have long been the cornerstone of treatment, providing symptom relief but no disease-modifying effects on the underlying sarcomere dysfunction.²

How Mavacamten Targets Myosin

Mavacamten is a small molecule that binds directly to cardiac myosin and inhibits its ability to split ATP, the energy currency that powers each contraction stroke.³ By slowing down that enzymatic activity, mavacamten reduces the number of myosin heads that engage with actin (the partner protein they pull against) at any given moment. Fewer engaged motors mean less force generated per beat.

The drug also speeds up the detachment of myosin heads that are already bound. Lab work on muscle fibers shows mavacamten increases the rates at which certain biochemical steps occur during the detachment process, contributing to faster relaxation of the muscle during diastole, the filling phase between contractions.⁴ That same research demonstrated that mavacamten reduces the sensitivity of the contraction apparatus to calcium, the ion that normally triggers each contraction. Lower calcium sensitivity means the muscle is less reactive, which helps counteract the hypercontractility caused by HCM mutations.

The Super-Relaxed State

One of the most distinctive aspects of mavacamten’s mechanism involves a specific resting configuration of cardiac myosin. In a healthy heart, a significant fraction of myosin motors are parked in a low-energy state where the two heads of each myosin molecule fold back on each other, forming what researchers call the interacting-heads motif. In this folded-back position, myosin barely uses any ATP. Think of it as a parking brake for the motor: the heads are physically tucked away and unavailable for contraction.

HCM mutations destabilize this parked state, releasing too many motors into the active pool. Mavacamten does the opposite: it promotes and stabilizes the folded-back, autoinhibited state.⁵ Detailed studies of two-headed myosin fragments confirmed that this autoinhibition is a property of the intact two-headed molecule, not something you can observe with a single motor head, and mavacamten specifically enhances it.⁶

High-resolution structural imaging has shown exactly how this works at an atomic level. When mavacamten binds, it stalls the motor in a primed but inactive configuration, reducing the internal dynamics the motor needs to grab onto actin and generate force. Within the two-headed molecule, these effects cascade: they increase the contact between the two motor heads, locking them more firmly into the folded-back motif.⁷ The net effect is fewer active motors, less contraction force, and less energy wasted on unnecessary work.

What Happens in the Heart

The molecular effects of mavacamten translate into several measurable changes in how the heart functions. The most immediate and clinically important is a reduction in the pressure gradient across the left ventricular outflow tract, the bottleneck where thickened muscle obstructs blood flow. In the EXPLORER-HCM trial, mavacamten reduced that gradient after exercise by an average of about 36 mm Hg more than placebo.⁸

Another striking finding from the same trial’s imaging analyses: roughly 81% of mavacamten-treated patients saw complete resolution of a phenomenon called systolic anterior motion of the mitral valve, where the mitral valve leaflet gets pulled into the outflow tract during contraction, worsening obstruction and causing mitral regurgitation. Only about a third of placebo patients experienced the same.⁹ By reducing how hard the ventricle squeezes, mavacamten removes the suction effect that drags the valve leaflet out of position.

Better Relaxation and Lower Filling Pressures

Because mavacamten speeds up cross-bridge detachment, it doesn’t just reduce contraction force; it also helps the ventricle relax and fill more easily. This is critical in HCM, where stiff, thickened muscle makes diastolic filling one of the main drivers of breathlessness and exercise intolerance.

In the VALOR-HCM study, which enrolled patients sick enough to be referred for surgical or catheter-based septal reduction, mavacamten improved diastolic function grade in about 29% of treated patients compared with roughly 13% on placebo. The ratio used to estimate filling pressures dropped significantly with mavacamten, and left atrial volumes shrank, both signs that the heart is filling under less strain.¹⁰ These diastolic improvements remained significant even after accounting for changes in obstruction and mitral regurgitation, suggesting mavacamten has a direct effect on how the muscle relaxes, not just an indirect benefit from relieving outflow tract blockage.

Similar diastolic gains have been confirmed in other cohorts: one study found filling-pressure markers fell substantially and left atrial volumes decreased by more than 20% over the treatment period.¹¹

Energy Savings and Structural Remodeling

A thickened, hypercontractile heart is an energy-hungry heart. By parking more myosin motors in the low-energy resting state, mavacamten reduces ATP consumption and oxygen demand in the hypertrophied muscle.¹² Over time, this energy recalibration appears to allow the heart to remodel favorably. After 30 weeks in the EXPLORER-HCM trial, mavacamten-treated patients showed a meaningful reduction in left ventricular mass index compared with placebo, and repeat cardiac MRI at nearly two years showed that remodeling persisted while contractile function remained normal.¹³ Maximum wall thickness and left atrial volume also decreased. These structural improvements go beyond what beta-blockers have achieved and raise the possibility that mavacamten is not just symptom relief but genuinely modifies the disease trajectory.

What the Trials Show for Symptoms and Exercise

EXPLORER-HCM enrolled 251 adults with symptomatic obstructive HCM. About 37% of mavacamten patients met the composite primary endpoint of improved exercise capacity and symptoms, compared with 17% on placebo. Peak oxygen consumption rose, symptom questionnaire scores improved, and roughly a third more mavacamten patients improved by at least one functional class.⁸ A secondary analysis of exercise testing parameters showed improvements in ventilatory efficiency, metabolic equivalents, and peak exercise time as well.¹⁴

For patients whose symptoms were severe enough to qualify for septal reduction therapy (surgical myectomy or alcohol septal ablation), the VALOR-HCM trial asked a blunt question: could mavacamten keep patients off the operating table? At 16 weeks, about 77% of placebo patients still met criteria for the procedure, versus only about 18% of those on mavacamten.¹⁵ Long-term follow-up through 128 weeks showed that the vast majority of patients stayed off surgery: only about 16% of the full study cohort met the composite endpoint that included undergoing the procedure.¹⁶

These benefits were consistent regardless of whether patients were also taking beta-blockers. Sub-group analyses showed similar improvements in symptoms, outflow tract gradients, left atrial volume, and biomarkers in beta-blocker users and non-users.¹⁷

Biomarker Changes Reflect the Mechanism

Two blood markers serve as a window into what mavacamten is doing inside the heart. NT-proBNP is released when heart muscle is stretched under pressure; cardiac troponin I leaks out when heart cells are injured or stressed. Both drop during mavacamten treatment. A meta-analysis pooling trial data found significant reductions in NT-proBNP relative to placebo, and a separate systematic review confirmed that both NT-proBNP and cardiac troponin I declined with treatment.¹⁸ ¹⁹ These declines align with the mechanism: less wall stress because the muscle is squeezing less aggressively, and less cellular injury because the energy supply-demand mismatch has improved.

Early-phase work has also looked at mavacamten in patients who have HCM but lack outflow tract obstruction. In a small study of non-obstructive HCM, mavacamten was well tolerated and produced significant reductions in NT-proBNP and troponin, suggesting improvement in myocardial wall stress even when obstruction isn’t the primary problem.²⁰ Larger trials in this population are ongoing.

The Safety Tradeoff and Monitoring Requirements

Because mavacamten’s entire purpose is to reduce how hard the heart squeezes, the most predictable risk is reducing it too much. If the left ventricular ejection fraction, which measures the percentage of blood pumped out with each beat, drops below about 50%, the drug has overshot. In the United States, mavacamten is available only through a restricted distribution program that requires regular monitoring of ejection fraction via echocardiography.

Real-world data from over 5,500 patients enrolled in this monitoring program showed that about 4.6% developed an ejection fraction below 50%, and about 1.3% were hospitalized for heart failure. Among patients who had been on the drug for at least a year, the rate of an ejection fraction dip was about 4%, and heart failure requiring hospitalization plus a low ejection fraction occurred in only about 0.2%, with those patients later able to resume treatment.²¹ These numbers suggest the risk is manageable with proper surveillance, but they also explain why the drug can’t be prescribed casually.

Why Genetics Matter for Dosing

Mavacamten is broken down in the liver primarily by a family of enzymes, and one of them, CYP2C19, varies widely between individuals because of inherited genetic differences. People who carry two loss-of-function copies of the CYP2C19 gene (known as poor metabolizers) clear the drug much more slowly, leading to higher blood levels and a greater risk of excessive suppression of heart function. The European Medicines Agency recommends genetic testing for CYP2C19 before starting mavacamten, with dose adjustments based on the result.²²

Drug interactions add another layer of complexity. Because mavacamten is processed by several of these liver enzymes, including CYP2C19, CYP2C9, and CYP2D6, medications that block or boost those enzymes can shift mavacamten levels unpredictably.²³ Common culprits include certain antifungal drugs, some antidepressants, and even grapefruit juice. This pharmacogenomic sensitivity is one reason mavacamten requires more careful management than a typical heart medication.

Does Genetic Subtype of HCM Affect Response?

HCM can be caused by mutations in different sarcomere genes, and not all patients carry an identifiable mutation at all. A natural question is whether mavacamten, which targets myosin directly, works better in patients whose specific mutation has been identified. Sub-group analysis from EXPLORER-HCM looked at this. Patients with a confirmed sarcomere gene mutation showed a strong treatment benefit, and patients without an identified mutation also improved, though the statistical confidence was somewhat wider in the mutation-negative group.²⁴ Improvements in outflow tract gradients, oxygen consumption, and functional class were observed in both groups. The drug’s mechanism, targeting the final common pathway of myosin hyperactivity, apparently works regardless of which upstream mutation created the problem.

How Aficamten Differs

Mavacamten is the first approved cardiac myosin inhibitor, but it is no longer the only one in late-stage development. Aficamten, a second-generation drug in the same class, also binds the myosin head and suppresses its activity, but at a different site and with a somewhat different molecular fingerprint. Aficamten is a more potent suppressor of a specific biochemical step (the release of phosphate, which commits myosin to its power stroke) and has a shallower dose-response curve, meaning there is a wider margin between a therapeutic dose and one that oversuppresses contraction.²⁵ Aficamten also has a shorter half-life, so its effects wear off faster if the drug is stopped or the dose needs to be adjusted. These differences may translate into a more forgiving safety profile, though head-to-head comparisons with mavacamten have not been completed.

Both drugs represent a fundamentally new approach. Rather than modulating the heart through its electrical or hormonal control systems, they go straight to the contractile protein. For a disease caused by too much motor activity, that directness is exactly the point.